Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NAMS, KRYS, MIRM, HLVX, Alpine Immune Sciences, and represent 38.61% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$34M), ORIC (+$28M), PEPG (+$22M), BBIO (+$21M), SLNO (+$18M), Adverum Biotechnologies (+$15M), PBYI (+$15M), GPCR (+$13M), APLT (+$13M), ALLO (+$13M).
- Started 7 new stock positions in ALLO, PBYI, MGX, PEPG, CGON, Adverum Biotechnologies, APLT.
- Reduced shares in these 10 stocks: MDGL (-$16M), DYN (-$16M), CRNX (-$14M), ETNB (-$12M), APGE (-$11M), Theseus Pharmaceuticals (-$8.6M), RYTM (-$7.8M), COGT (-$7.1M), ACAD, Mirati Therapeutics.
- Sold out of its positions in APGE, CRNX, DYN, MDGL, Mirati Therapeutics, Theseus Pharmaceuticals.
- Frazier Life Sciences Management was a net buyer of stock by $123M.
- Frazier Life Sciences Management has $2.4B in assets under management (AUM), dropping by 26.71%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 50 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 12.2 | $289M | 12M | 23.65 |
|
|
Krystal Biotech (KRYS) | 7.4 | $176M | 989k | 177.93 |
|
|
Mirum Pharmaceuticals (MIRM) | 6.9 | $163M | 6.5M | 25.12 |
|
|
Hillevax (HLVX) | 6.9 | $163M | 9.8M | 16.63 |
|
|
Alpine Immune Sciences | 5.2 | $124M | 3.1M | 39.64 |
|
|
Phathom Pharmaceuticals (PHAT) | 4.5 | $107M | 10M | 10.62 |
|
|
Bridgebio Pharma (BBIO) | 4.5 | $106M | +25% | 3.4M | 30.92 |
|
Rhythm Pharmaceuticals (RYTM) | 4.0 | $95M | -7% | 2.2M | 43.33 |
|
Arcutis Biotherapeutics (ARQT) | 3.7 | $87M | 8.8M | 9.91 |
|
|
Vaxcyte (PCVX) | 3.3 | $78M | -2% | 1.1M | 68.31 |
|
Tarsus Pharmaceuticals (TARS) | 2.7 | $65M | 1.8M | 36.35 |
|
|
Edgewise Therapeutics (EWTX) | 2.5 | $60M | +23% | 3.3M | 18.24 |
|
Oric Pharmaceuticals (ORIC) | 2.4 | $57M | +93% | 4.1M | 13.75 |
|
Apellis Pharmaceuticals (APLS) | 2.2 | $52M | 885k | 58.78 |
|
|
Disc Medicine (IRON) | 2.1 | $49M | 785k | 62.26 |
|
|
Verona Pharma Sponsored Ads (VRNA) | 2.0 | $49M | 3.0M | 16.09 |
|
|
Kalvista Pharmaceuticals (KALV) | 1.8 | $44M | 3.7M | 11.86 |
|
|
Rocket Pharmaceuticals (RCKT) | 1.8 | $42M | +2% | 1.6M | 26.94 |
|
Soleno Therapeutics (SLNO) | 1.6 | $38M | +88% | 876k | 42.80 |
|
Macrogenics (MGNX) | 1.5 | $36M | +2% | 2.5M | 14.72 |
|
Aerovate Therapeutics (AVTE) | 1.5 | $36M | 1.2M | 29.57 |
|
|
Cg Oncology (CGON) | 1.4 | $34M | NEW | 770k | 43.90 |
|
Merus N V (MRUS) | 1.4 | $34M | 747k | 45.03 |
|
|
Revolution Medicines (RVMD) | 1.4 | $32M | 998k | 32.23 |
|
|
Autolus Therapeutics Spon Ads (AUTL) | 1.2 | $30M | +23% | 4.6M | 6.38 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 1.1 | $27M | +98% | 629k | 42.86 |
|
Trevi Therapeutics (TRVI) | 1.1 | $26M | 7.4M | 3.45 |
|
|
Silence Therapeutics Ads (SLN) | 1.0 | $25M | +30% | 1.1M | 21.60 |
|
Deciphera Pharmaceuticals | 1.0 | $23M | +42% | 1.5M | 15.73 |
|
Pepgen (PEPG) | 0.9 | $22M | NEW | 1.5M | 14.70 |
|
Anaptysbio Inc Common (ANAB) | 0.9 | $20M | 900k | 22.52 |
|
|
Savara (SVRA) | 0.8 | $20M | 4.0M | 4.98 |
|
|
Cerevel Therapeutics Hldng I (CERE) | 0.7 | $17M | 393k | 42.27 |
|
|
Agios Pharmaceuticals (AGIO) | 0.6 | $15M | 523k | 29.24 |
|
|
Adverum Biotechnologies | 0.6 | $15M | NEW | 1.1M | 14.14 |
|
Puma Biotechnology (PBYI) | 0.6 | $15M | NEW | 2.8M | 5.30 |
|
Tyra Biosciences (TYRA) | 0.6 | $14M | -18% | 832k | 16.40 |
|
Applied Therapeutics (APLT) | 0.6 | $13M | NEW | 2.0M | 6.80 |
|
Allogene Therapeutics (ALLO) | 0.5 | $13M | NEW | 2.9M | 4.47 |
|
Arvinas Ord (ARVN) | 0.5 | $12M | 285k | 41.28 |
|
|
89bio (ETNB) | 0.5 | $12M | -50% | 1.0M | 11.64 |
|
ACADIA Pharmaceuticals (ACAD) | 0.4 | $8.7M | -35% | 470k | 18.49 |
|
Cogent Biosciences (COGT) | 0.3 | $6.3M | -53% | 937k | 6.72 |
|
Intellia Therapeutics (NTLA) | 0.2 | $5.6M | 204k | 27.51 |
|
|
Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.2 | $5.5M | 500k | 11.04 |
|
|
An2 Therapeutics (ANTX) | 0.2 | $4.5M | 1.4M | 3.25 |
|
|
Metagenomi (MGX) | 0.1 | $2.9M | NEW | 279k | 10.55 |
|
Gritstone Oncology Ord (GRTS) | 0.1 | $2.6M | 1.0M | 2.57 |
|
|
Bluebird Bio (BLUE) | 0.1 | $2.2M | 1.7M | 1.28 |
|
|
Aclaris Therapeutics (ACRS) | 0.0 | $328k | 264k | 1.24 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022